Patient‐reported tolerability of veliparib combined with cisplatin and etoposide for treatment of extensive stage small cell lung cancer: Neurotoxicity and adherence data from the ECOG ACRIN cancer research group E2511 phase II randomized trial

OBJECTIVES: The ECOG‐ACRIN Cancer Research Group trial E2511 recently demonstrated a potential benefit for the addition of veliparib to cisplatin‐etoposide (CE) in patients with extensive stage small cell lung cancer (ES‐SCLC) in a phase II randomized controlled trial. Secondary trial endpoints incl...

Descripción completa

Detalles Bibliográficos
Autores principales: Steffen McLouth, Laurie E., Zhao, Fengmin, Owonikoko, Taofeek K., Feliciano, Josephine L., Mohindra, Nisha A., Dahlberg, Suzanne E., Wade, James L., Srkalovic, Gordan, Lash, Bradley W., Leach, Joseph W., Leal, Ticiana A., Aggarwal, Charu, Cella, David, Ramalingam, Suresh S., Wagner, Lynne I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7571824/
https://www.ncbi.nlm.nih.gov/pubmed/32860331
http://dx.doi.org/10.1002/cam4.3416

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7571824/
https://www.ncbi.nlm.nih.gov/pubmed/32860331
http://dx.doi.org/10.1002/cam4.3416

Ejemplares similares